Coagulation

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

CYBER ENVIRO-TECH, INC ACQUIRES STABLEX AND SECURES EXCLUSIVE GLOBAL LICENSES TO INTELLECTUAL PROPERTY RIGHTS FROM KAM BIOTECHNOLOGY LTD.

Retrieved on: 
Tuesday, February 27, 2024
Acquisition, Soil, Biotechnology, Coagulation, OTC Markets Group, Hazardous waste, Patent, Longevity, Partnership, Fine chemical

Having initially secured US rights in mid-2023, CETI has opted to extend its exclusive license rights globally in light of promising results observed by several of its domestic and international clients.

Key Points: 
  • Having initially secured US rights in mid-2023, CETI has opted to extend its exclusive license rights globally in light of promising results observed by several of its domestic and international clients.
  • This strategic move is poised to significantly augment CETI's commitment to environmentally sustainable solutions in the remediation of industrial wastewater.
  • KAM's Stablex, alongside the other patented licenses secured from KAM, plays a pivotal role in neutralizing hazardous chemical interactions during CETI's remediation processes for soil, sludge, and contaminated water.
  • Through this new partnership, CETI is poised to harness KAM's expertise in microbiological oil spill and soil remediation solutions.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, Other Health, Technology, Stem Cells, Pharmaceutical, Surgery, Medical Devices, Genetics, Clinical Trials, Biotechnology, Science, Software, Veterinary, Other Science, Research, Health, Meiji University, Embryology, Cell, Doctor of Philosophy, Coagulation, Inflammation, Quality of life, Pelvic floor dysfunction, Transgene, Transplant, Genome, Patient, Gene, Kidney, Mortality, Tissue, Vaccine

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice

Retrieved on: 
Tuesday, February 6, 2024
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Surgery, Artificial Intelligence, Oncology, Research, Medical Devices, Genetics, Health Technology, Science, Clinical Trials, Coagulation, Patient, BIAF, Lung cancer, Medicine, Cryotherapy, Physician, Lung, Plasma

Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.

Key Points: 
  • Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath® Lung into its practice to aid in the detection of early-stage lung cancer.
  • “As a clinician, I see hundreds of patients a year who can directly benefit from CyPath® Lung, bioAffinity’s patient-friendly, noninvasive test for lung cancer.
  • As a researcher, I am excited about the Company’s ongoing studies to advance CyPath® Lung, as well as noninvasive tests for other lung diseases,” Dr. Bansal said.
  • Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board.

eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor

Retrieved on: 
Thursday, January 18, 2024
Other Health, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hospitals, Genetics, Data Management, Science, Technology, Veterinary, Clinical Trials, General Health, FDA, Biotechnology, Surgery, Health, Mortality, Hope, Family, Patient, Coagulation, Liver failure, Multimedia, ELC, MFS, Pelvic floor dysfunction, Gift, Gene, University, Drug discovery, Risk, Perfusion, Transgene, IND, Food, Pressure, Liver, Inflammation, Genome, Organization, CPTC, Bile, Cell, Trial of the century, Dietary supplement

The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.

Key Points: 
  • The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
  • The efficacy of existing liver support options is limited, and patients in liver failure face a high risk of mortality.
  • For some patients, utilizing a human-compatible, genetically engineered porcine whole liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant.
  • The genetically engineered porcine liver used in this study carried the same genetics as the porcine kidneys used in the landmark preclinical study recently published in Nature .

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA

Retrieved on: 
Thursday, January 4, 2024
Clopidogrel, Coagulation, FDA, Acute coronary syndrome, Stroke, Moyamoya disease, Patient, Food, NDA, Pharmaceutical industry

This filing marks a significant milestone as Jiangsu Vcare's first NDA submission from its innovative drug pipeline.

Key Points: 
  • This filing marks a significant milestone as Jiangsu Vcare's first NDA submission from its innovative drug pipeline.
  • This NDA filing builds on continuous dialogues with the FDA and is supported by robust nonclinical data and clinical studies conducted in both China and US.
  • Vicagrel, a novel oral P2Y12 receptor antagonist, represents Jiangsu Vcare's commitment to addressing unmet clinical needs with innovative approaches.
  • This NDA filing reflects more than ten years of persistent innovation and dedication by Jiangsu Vcare.

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, January 3, 2024
Phase, Coagulation, Food, Emergency medicine, Risk, Vitamin K, PCC, Hemostasis, FDA, Warfarin, Bleeding, INR, Massachusetts General Hospital, Hospital, Thrombophilia, MD, Doctor of Philosophy, Factor X, Factor IX, Clinical trial, Prothrombin time, Trial of the century, Coagulation factor VII, Octapharma, VKA, Patient, Safety, Harvard Medical School, Thrombin, Pharmaceutical industry

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

Key Points: 
  • The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
  • Octapharma has the Balfaxar® production flexibility to ensure consistent supply for hospitals and medical providers.
  • "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future.
  • Balfaxar® met the primary endpoint of hemostatic efficacy in patients on a vitamin K antagonist undergoing urgent surgery with significant bleeding risk.

Pre-Eclampsia Drug Pipeline Research Report 2023: Comprehensive Insights into 5+ Companies and Portfolios of 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 14, 2023
Health, Other Health, NDA, Protein, Research, DNA, Thrombophilia, Disease, Clinical trial, CAD, Congenital iodine deficiency syndrome, Mergers and acquisitions, Therapy, DIC, Phase, Coagulation, Discovery, News, Purpura, Pharmaceutical industry, Pre-eclampsia

Discover the dynamic landscape of Pre-Eclampsia research with our report, offering comprehensive insights into 5+ leading companies and their portfolios of 5+ pipeline drugs.

Key Points: 
  • Discover the dynamic landscape of Pre-Eclampsia research with our report, offering comprehensive insights into 5+ leading companies and their portfolios of 5+ pipeline drugs.
  • Our report also shines a light on inactive pipeline projects within this domain.
  • Dive into our thorough assessment, which encompasses a comprehensive commercial evaluation of Pre-Eclampsia alongside a clinical analysis of ongoing pipeline projects.
  • Experience the collaborative efforts of companies and academic institutions as they tackle challenges and explore opportunities within Pre-Eclampsia research and development.

UroFiber SuperPulsed Thulium Fiber Laser System Officially Debuts at MEDICA 2023

Retrieved on: 
Thursday, November 30, 2023
MEDICA, TFL, Multimedia, Hemostasis, BPH, YAG, Coagulation, Rock, Medical device

DUSSELDORF, Germany, Nov. 30, 2023 /PRNewswire/ -- UroFiber SuperPulsed Thulium Fiber Laser System , developed by Rhein Laser Technologies Ltd., a pioneer in medical laser technology, made its first appearance at the esteemed MEDICA 2023 in Germany.

Key Points: 
  • DUSSELDORF, Germany, Nov. 30, 2023 /PRNewswire/ -- UroFiber SuperPulsed Thulium Fiber Laser System , developed by Rhein Laser Technologies Ltd., a pioneer in medical laser technology, made its first appearance at the esteemed MEDICA 2023 in Germany.
  • This groundbreaking system sets a new standard for urological procedures as the world's first 1940nm 150W SuperPulsed Thulium Fiber Laser (TFL) system for perfectly treating both stone lithotripsy and BPH enucleation.
  • An impressive array of studies has validated the clinical efficacy of SuperPulsed Thulium Fiber Laser System in terms of tissue ablation, coagulation and hemostasis.
  • The UroFiber SuperPulsed Thulium Fiber Laser System showcased at MEDICA heralds a paradigm shift in medical surgery.